Miami, FL AND NEW YORK, NY, FEBRUARY 6, 2017
Noven Appoints Mark Jackson
as Vice President – Quality
Noven Pharmaceuticals, Inc. today announced the appointment of Mark Jackson, as the company’s new Vice President – Quality. In this role, Jackson will be responsible for overseeing all of the Company’s activities related to Quality Assurance, Quality Control and Compliance. Jackson will report to Jeff Mihm, Noven’s Chief Executive Officer.
Jackson has over 30 years’ experience in the pharmaceutical and medical device industries. He joins Noven from HeartWare, Inc., a global medical device company specializing in the treatment of heart failure, where he served as the Vice President of Quality and Design Assurance. Previously, Jackson was at Baxter Healthcare Corp. where he held positions of increasing responsibility including, Vice President Medical Products Quality, Vice President Quality, Renal Division/Global Technical Service and Plant Manager.
Regarding Jackson’s appointment, Mihm said, “Mark has a proven track record for being an accomplished leader and establishing a culture of quality excellence. I am very pleased to have him joining Noven, and I am confident he will be a great asset in helping us to achieve our commitment to advancing patient care through transdermal drug delivery.”
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Noven’s mission is to develop and offer pharmaceutical products that meaningfully benefit patients around the world, with a commitment to advancing patient care through transdermal drug delivery. Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., serving as Hisamitsu’s U.S. platform in prescription pharmaceuticals, and helping Hisamitsu bring the benefits of patch therapy to the world. For more information about Noven, visit www.noven.com. For information about Hisamitsu, visit www.hisamitsu.co.jp/english.
Noven Pharmaceuticals, Inc.